LAUSR

ObjectiveTo observe the clinical effects of tuina plus Western medication for functional dyspepsia (FD) due to liver qi stagnation and spleen deficiency.Methodstotal of 72 patients in conformity with the inclusion criteria of FD were randomly divided into an observation group and a control group based upon the random number table, 36 cases in each group. The control group was treated with mosapride citrate dispersible tablets, and the observation group was treated with the same tablets plus tuina. Before the treatment and 4 weeks after the treatment, the clinical symptoms, quality of life (QOL) and depression severity were observed by the scale, and were followed up two months later after the treatment for assessment of the clinical effects.ResultsAfter the treatment and at the follow-up, the symptom scores of FD and the sores of Hamilton depression rating scale (HAMD) in both groups decreased, and the scores in Chinese version of quality of life questionnaire for functional digestive disorders (Chin-FDDQL) increased, with statistically significant differences in comparison with the same group before the treatment (all P<0.05). In comparison between the two groups at the same time point after the treatment, the scores of FD symptoms, HAMD and Chin-FDDQL were improved better in the observation group than those in the control group, with statistically significant differences (all P<0.05). The total effective rates at the follow-up were 91.7% in the observation group and 75.0% in the control group, without statistical difference between the two groups (P>0.05). The rate of clinical cure and remarkable effect was 66.7% in the observation group, higher than 41.7% in the control group, it is higher in the observation group than that in the control group, with a statistically significant difference between the two groups (P<0.05).ConclusionTuina plus Western medication is precise in the therapeutic effects for FD due to liver qi stagnation and spleen deficiency and can effectively relieve clinical symptoms, elevate the QOL and alleviate depression severity of the patients. Moreover, it’s better than the treatment by Western medication alone in the long-term therapeutic effects.摘要目的观察推拿联合西药治疗肝郁脾虚证功能性消化不良(FD)的临床疗效。方法将符合FD纳入标准的 72例患者按随机数字表法随机分为观察组与对照组, 每组36例。 对照组予以枸橼酸莫沙必利分散片口服, 观察组在此基础上加用推拿治疗。 治疗前及治疗4星期后通过量表观察两组患者临床症状、 生活质量及抑郁程度, 并于治疗结束2个月后进行随访评价临床疗效。结果两组患者治疗后及随访时FD症状评分、 汉密顿抑郁量表(HAMD) 评分均下降, 中文版功能性消化不良生存质量量表(Chin-FDDQL)评分升高, 与本组治疗前差异均具有统计学意义(均P<0.05)。 两组治疗后同一时间点比较, 观察组的FD症状评分、 HAMD评分及Chin-FDDQL评分的改善情况均优于对照组, 组间差异均有统计学意义(均P<0.05)。随访时观察组的总有效率为91.7%, 对照组为75.0%, 组间差异 无统计学意义(P>0.05)。观察组的愈显率为66.7%, 对照组的愈显率为41.7%, 观察组愈显率高于对照组, 组间差异有统计学意义(P<0.05)。结论推拿联合西药治疗肝郁脾虚证FD疗效确切, 能有效改善患者的临床症状, 提高 其生活质量, 减轻抑郁程度, 且远期疗效优于单纯西药治疗。